Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115514008> ?p ?o ?g. }
- W2115514008 endingPage "2048" @default.
- W2115514008 startingPage "2037" @default.
- W2115514008 abstract "Purpose The purpose of this systematic review was to synthesize the available Level I and Level II literature on platelet-rich plasma (PRP) as a therapeutic intervention in the management of symptomatic knee osteoarthritis (OA). Methods A systematic review of Medline, Embase, Cochrane Central Register of Controlled Trials, PubMed, and www.clinicaltrials.gov was performed to identify all randomized controlled trials and prospective cohort studies that evaluated the clinical efficacy of PRP versus a control injection for knee OA. A random-effects model was used to evaluate the therapeutic effect of PRP at 24 weeks by use of validated outcome measures (Western Ontario and McMaster Universities Arthritis Index, visual analog scale for pain, International Knee Documentation Committee Subjective Knee Evaluation Form, and overall patient satisfaction). Results Six Level I and II studies satisfied our inclusion criteria (4 randomized controlled trials and 2 prospective nonrandomized studies). A total of 577 patients were included, with 264 patients (45.8%) in the treatment group (PRP) and 313 patients (54.2%) in the control group (hyaluronic acid [HA] or normal saline solution [NS]). The mean age of patients receiving PRP was 56.1 years (51.5% male patients) compared with 57.1 years (49.5% male patients) for the group receiving HA or NS. Pooled results using the Western Ontario and McMaster Universities Arthritis Index scale (4 studies) showed that PRP was significantly better than HA or NS injections (mean difference, −18.0 [95% confidence interval, −28.8 to −8.3]; P < .001). Similarly, the International Knee Documentation Committee scores (3 studies) favored PRP as a treatment modality (mean difference, 7.9 [95% confidence interval, 3.7 to 12.1]; P < .001). There was no difference in the pooled results for visual analog scale score or overall patient satisfaction. Adverse events occurred more frequently in patients treated with PRP than in those treated with HA/placebo (8.4% v 3.8%, P = .002). Conclusions As compared with HA or NS injection, multiple sequential intra-articular PRP injections may have beneficial effects in the treatment of adult patients with mild to moderate knee OA at approximately 6 months. There appears to be an increased incidence of nonspecific adverse events among patients treated with PRP. Level of evidence Level II, systematic review of Level I and II studies. The purpose of this systematic review was to synthesize the available Level I and Level II literature on platelet-rich plasma (PRP) as a therapeutic intervention in the management of symptomatic knee osteoarthritis (OA). A systematic review of Medline, Embase, Cochrane Central Register of Controlled Trials, PubMed, and www.clinicaltrials.gov was performed to identify all randomized controlled trials and prospective cohort studies that evaluated the clinical efficacy of PRP versus a control injection for knee OA. A random-effects model was used to evaluate the therapeutic effect of PRP at 24 weeks by use of validated outcome measures (Western Ontario and McMaster Universities Arthritis Index, visual analog scale for pain, International Knee Documentation Committee Subjective Knee Evaluation Form, and overall patient satisfaction). Six Level I and II studies satisfied our inclusion criteria (4 randomized controlled trials and 2 prospective nonrandomized studies). A total of 577 patients were included, with 264 patients (45.8%) in the treatment group (PRP) and 313 patients (54.2%) in the control group (hyaluronic acid [HA] or normal saline solution [NS]). The mean age of patients receiving PRP was 56.1 years (51.5% male patients) compared with 57.1 years (49.5% male patients) for the group receiving HA or NS. Pooled results using the Western Ontario and McMaster Universities Arthritis Index scale (4 studies) showed that PRP was significantly better than HA or NS injections (mean difference, −18.0 [95% confidence interval, −28.8 to −8.3]; P < .001). Similarly, the International Knee Documentation Committee scores (3 studies) favored PRP as a treatment modality (mean difference, 7.9 [95% confidence interval, 3.7 to 12.1]; P < .001). There was no difference in the pooled results for visual analog scale score or overall patient satisfaction. Adverse events occurred more frequently in patients treated with PRP than in those treated with HA/placebo (8.4% v 3.8%, P = .002). As compared with HA or NS injection, multiple sequential intra-articular PRP injections may have beneficial effects in the treatment of adult patients with mild to moderate knee OA at approximately 6 months. There appears to be an increased incidence of nonspecific adverse events among patients treated with PRP." @default.
- W2115514008 created "2016-06-24" @default.
- W2115514008 creator A5003636337 @default.
- W2115514008 creator A5008229518 @default.
- W2115514008 creator A5011438512 @default.
- W2115514008 creator A5016619046 @default.
- W2115514008 creator A5018173994 @default.
- W2115514008 creator A5046702075 @default.
- W2115514008 creator A5063617403 @default.
- W2115514008 creator A5066675288 @default.
- W2115514008 creator A5068626149 @default.
- W2115514008 creator A5088099380 @default.
- W2115514008 date "2013-12-01" @default.
- W2115514008 modified "2023-10-15" @default.
- W2115514008 title "The Efficacy of Platelet-Rich Plasma in the Treatment of Symptomatic Knee Osteoarthritis: A Systematic Review With Quantitative Synthesis" @default.
- W2115514008 cites W118417989 @default.
- W2115514008 cites W1716794597 @default.
- W2115514008 cites W1935366683 @default.
- W2115514008 cites W1967057044 @default.
- W2115514008 cites W1969744221 @default.
- W2115514008 cites W1982666000 @default.
- W2115514008 cites W1984196156 @default.
- W2115514008 cites W1985156946 @default.
- W2115514008 cites W1994143652 @default.
- W2115514008 cites W1994898034 @default.
- W2115514008 cites W1995229018 @default.
- W2115514008 cites W1996247217 @default.
- W2115514008 cites W2002535969 @default.
- W2115514008 cites W2005611861 @default.
- W2115514008 cites W2007511577 @default.
- W2115514008 cites W2009242989 @default.
- W2115514008 cites W2010278668 @default.
- W2115514008 cites W2012504160 @default.
- W2115514008 cites W2013259659 @default.
- W2115514008 cites W2017718314 @default.
- W2115514008 cites W2020020571 @default.
- W2115514008 cites W2020466745 @default.
- W2115514008 cites W2022851289 @default.
- W2115514008 cites W2024962472 @default.
- W2115514008 cites W2025603090 @default.
- W2115514008 cites W2033889139 @default.
- W2115514008 cites W2034055577 @default.
- W2115514008 cites W2034632069 @default.
- W2115514008 cites W2035963415 @default.
- W2115514008 cites W2036914540 @default.
- W2115514008 cites W2037328562 @default.
- W2115514008 cites W2043351904 @default.
- W2115514008 cites W2046601598 @default.
- W2115514008 cites W2053432078 @default.
- W2115514008 cites W2056691177 @default.
- W2115514008 cites W2064512855 @default.
- W2115514008 cites W2064687104 @default.
- W2115514008 cites W2066496557 @default.
- W2115514008 cites W2076438700 @default.
- W2115514008 cites W2092156139 @default.
- W2115514008 cites W2094346517 @default.
- W2115514008 cites W2095239454 @default.
- W2115514008 cites W2096813909 @default.
- W2115514008 cites W2098656787 @default.
- W2115514008 cites W2099204150 @default.
- W2115514008 cites W2101886884 @default.
- W2115514008 cites W2105290236 @default.
- W2115514008 cites W2107383181 @default.
- W2115514008 cites W2108738802 @default.
- W2115514008 cites W2109124004 @default.
- W2115514008 cites W2109577600 @default.
- W2115514008 cites W2112653010 @default.
- W2115514008 cites W2114864896 @default.
- W2115514008 cites W2118727609 @default.
- W2115514008 cites W2120845101 @default.
- W2115514008 cites W2125435699 @default.
- W2115514008 cites W2125605937 @default.
- W2115514008 cites W2126930838 @default.
- W2115514008 cites W2128827515 @default.
- W2115514008 cites W2128845211 @default.
- W2115514008 cites W2129266770 @default.
- W2115514008 cites W2132844854 @default.
- W2115514008 cites W2139523975 @default.
- W2115514008 cites W2141157018 @default.
- W2115514008 cites W2161739351 @default.
- W2115514008 cites W2164434561 @default.
- W2115514008 cites W2164661751 @default.
- W2115514008 cites W2164816019 @default.
- W2115514008 cites W2165797485 @default.
- W2115514008 cites W2167775808 @default.
- W2115514008 cites W2168387142 @default.
- W2115514008 cites W2169333887 @default.
- W2115514008 cites W2171115512 @default.
- W2115514008 cites W2327880879 @default.
- W2115514008 cites W4254460683 @default.
- W2115514008 cites W88203146 @default.
- W2115514008 cites W1877291068 @default.
- W2115514008 doi "https://doi.org/10.1016/j.arthro.2013.09.006" @default.
- W2115514008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24286802" @default.
- W2115514008 hasPublicationYear "2013" @default.
- W2115514008 type Work @default.
- W2115514008 sameAs 2115514008 @default.
- W2115514008 citedByCount "179" @default.